Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Rain Therapeutics Q2 EPS $(0.39) Beats $(0.60) Estimate

Rain Therapeutics (NASDAQ:RAIN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.60) by 35 percent.

byBill Haddad

August 10, 2021

1 minute read

Rain Therapeutics (NASDAQ:RAIN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.60) by 35 percent.

Credit Suisse Initiates Coverage On Carlyle Group with Outperform Rating, Announces Price Target of $38.5

By Benzinga Newsdesk

Today, 4:38 AM

Credit Suisse analyst William Katz initiates coverage on Carlyle Group (NASDAQ:CG) with a Outperform rating and announces Price Target of $38.5.

Price Over Earnings Overview: Jacobs Engineering Group

By Benzinga Insights

Today, 4:38 AM

$1000 Invested In This Stock Over The Last 5 Years, Would Be Worth This Much

By Benzinga Insights

Today, 4:38 AM

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 5 years by 13.08% on an annualized basis.

ABT

GlaxoSmithKline Spotlights Encouraging Data For Anemia Drug

By Vandana Singh

Today, 4:38 AM

GlaxoSmithKline plc (NYSE:GSK) announced positive results from the ASCEND program comprised of five Phase 3 studies assessing daprodustat for anemia due…

GSK

Rain Therapeutics Q2 EPS $(0.39) Beats $(0.60) Estimate

Related Posts

Credit Suisse Initiates Coverage On Carlyle Group with Outperform Rating, Announces Price Target of $38.5

Price Over Earnings Overview: Jacobs Engineering Group

$1000 Invested In This Stock Over The Last 5 Years, Would Be Worth This Much

GlaxoSmithKline Spotlights Encouraging Data For Anemia Drug